Background:Depression is a mental health disorder characterized by persistent feelings of sadness, hopelessness, and a loss of interest in activities that were once enjoyable. The present study was conducted to assess the efficacy of mirtazapine in depression. Materials & Methods:50 patients diagnosed with depression of both genderswere divided into two groups. In Group A (n=30) patients received conventional SSRIs for 6 weeks. In Group B (n=30) patients received conventional SSRIs with low-dose mirtazapine for 6 weeks. Patients were evaluated at baseline and 6 weeks. Results: In group I, males were 12 and females were 13 and in group II, males were 11 and females were 14.HDRS score in group I and II at baseline found to be 20.5 and 20.6 and at 6 weeks was 10.2 and 7.4 respectively. MADRS score at baseline was 28.5 and 28.6 and at 6 weeks was 14.2 and 11.3 respectively. ADI score at baseline was 19.7 and 18.3 and at 6 weeks was 8.9 and 6.7 respectively. The difference was significant (P< 0.05). Conclusion: When compared to the baseline, the HDRS, MADRS, and ADI scores in both therapy groups significantly decreased. Patients receiving additional low-dose mirtazapine, however, experienced an earlier onset of action and better response as compared to SSRI alone.